Home   About this service   Get the news  
+32 2 743 34 03

 Belgium  Other Countries
Page : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - ...
UCB [BE0003739530/UCB]   
[18/01/2023]

UCB : UCB Media Room: Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

https://mb.cision.com/Public/18595/3698956/a1fc4b3ef46b9029_800x800ar.png Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab = Phase 3 Studies in Axial Spondyloarthritis =C2=B7 Publication of 24week results from the BE MOBILE 1 and BE MOBILE 2 = studies, evaluating bimekizumab, an IL17A and IL17F inhibitor, across the= full spectrum of axial... See more
 
UCB [BE0003739530/UCB]   
[09/01/2023]

UCB : UCB Media Room: Financial update

https://mb.cision.com/Public/18595/3694402/b7653f0cf6bf74d6_800x800ar.png UCBs financial update =C2=B7 2022 total revenue and adjusted EBITDA margin at the upper end of th= e guided range =C2=B7 Cimzia^=C2=AE reached its peak sales target of =E2=82=AC 2bn in 2022 =C2=B7 Fintepla^=C2=AE peak sales expected to reach =E2=82=AC 800 million b= y 2027 Brussels Belgium, 9 January 2022... See more
 
UCB [BE0003739530/UCB]   
[06/01/2023]

UCB : UCB Media Room: rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review

https://mb.cision.com/Public/18595/3693925/86e384ee3a575ab3_800x800ar.png UCB announces rozanolixizumab BLA for the treatment of generalized myast= henia gravis filed with U.S. FDA and designated for Priority Review =C2=B7 Biologic License Application BLA designated Priority Review by FDA= and seeks approval for rozanolixizumab for the treatment of adults with ge= neralized... See more
 
UCB [BE0003739530/UCB]   
[23/12/2022]

UCB : UCB Media Room: FDA Acceptance of BLA Resubmission for Bimekizumab

https://mb.cision.com/Public/18595/3689260/9662353673d9bc59_800x800ar.png UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab =C2=B7 The FDA designated the BLA resubmission as =E2=80=98Class 2=E2=80=99= with a sixmonth review period =C2=B7 The FDA action is expected in Q2 2023=C2=A0 Brussels Belgium, 23 December 2022 =E2=80=93 07:00 CET =E2=80=93 UCB, a= global... See more
 
UCB [BE0003739530/UCB]   
[19/12/2022]

UCB : UCB Media Room: FINTEPLA®▼ (fenfluramine) Positive CHMP Opinion

https://mb.cision.com/Public/18595/3686694/bcce151eae89c40e_800x800ar.png FINTEPLA^=C2=AE=E2=96=BC fenfluramine oral solution recommended for ap= proval in the EU for adjunctive treatment of seizures associated with Lenno= xGastaut syndrome LGS =C2=B7 Recommendation based on Phase 3 study data demonstrating safety and = efficacy in the most difficult to treat seizure types, including... See more